Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LONP1 | P36776 | 13/20 | 0.68 |
| ▸ | PSMB5 | P28074 | 11/20 | 0.68 |
| ▸ | PSMB8 | P28062 | 10/20 | 0.68 |
| ▸ | PSMB9 | P28065 | 10/20 | 0.68 |
| ▸ | PSMB6 | P28072 | 10/20 | 0.68 |
| ▸ | PSMB10 | P40306 | 10/20 | 0.68 |
| ▸ | PSMB11 | A5LHX3 | 9/20 | 0.68 |
| ▸ | PSMA7 | O14818 | 9/20 | 0.68 |
| ▸ | PSMB1 | P20618 | 9/20 | 0.68 |
| ▸ | PSMA1 | P25786 | 9/20 | 0.68 |
| ▸ | PSMA2 | P25787 | 9/20 | 0.68 |
| ▸ | PSMA3 | P25788 | 9/20 | 0.68 |
| ▸ | PSMA4 | P25789 | 9/20 | 0.68 |
| ▸ | PSMA5 | P28066 | 9/20 | 0.68 |
| ▸ | PSMB4 | P28070 | 9/20 | 0.68 |
| ▸ | PSMB3 | P49720 | 9/20 | 0.68 |
| ▸ | PSMB2 | P49721 | 9/20 | 0.68 |
| ▸ | PSMA6 | P60900 | 9/20 | 0.68 |
| ▸ | PSMA8 | Q8TAA3 | 9/20 | 0.68 |
| ▸ | PSMB7 | Q99436 | 9/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688075 | 1.00 | LONP1 (0.68) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL13078869 | 0.90 | CTSL (0.71) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL535688 | 0.90 | LONP1 (0.71) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL535687 | 0.90 | LONP1 (0.71) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL3926604 | 0.88 | LONP1 (0.69) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL12521571 | 0.87 | PSMB5 (0.74) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL3926607 | 0.86 | LONP1 (0.67) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL25003548 | 0.85 | CTSL (0.69) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL3083268 | 0.85 | CTSL (0.69) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL25110920 | 0.85 | LONP1 (0.72) | LONP1PSMB5PSMB8PSMB9PSMB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016059515-A1 | BORTEZOMIB FORMULATIONS | SHILPA MEDICARE LIMITED (IN) | 2016-04-21 | — | — | WO | disclosed |
| US-20150290277-A1 | PHARMACEUTICAL COMPOSITION | SUN PHARMA ADVANCED RES CO LTD (IN) | 2015-10-15 | — | — | US | disclosed |
| US-20150290277-A1 | PHARMACEUTICAL COMPOSITION | SUN PHARMA ADVANCED RES CO LTD (IN) | 2015-10-15 | — | — | US | disclosed |
| US-9095514-B2 | Pharmaceutical composition | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2015-08-04 | — | — | US | disclosed |
| US-9095514-B2 | Pharmaceutical composition | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2015-08-04 | — | — | US | disclosed |
| WO-2014102755-A1 | BORTEZOMIB FORMULATIONS | SHILPA MEDICARE LIMITED (IN) | 2014-07-03 | — | — | WO | disclosed |
| US-20110275597-A1 | PHARMACEUTICAL COMPOSITION | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2011-11-10 | — | — | US | disclosed |
| US-20110275597-A1 | PHARMACEUTICAL COMPOSITION | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2011-11-10 | — | — | US | disclosed |
| WO-2010089768-A2 | PHARMACEUTICAL COMPOSITION | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2010-08-12 | — | — | WO | disclosed |
| WO-2009067453-A1 | COMBINATIONS OF HDAC INHIBITORS AND PROTEASOME INHIBITORS | SYNDAX PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275597-A1 | PHARMACEUTICAL COMPOSITION | BCAT2, TTR, BCAT1 | LONP1 1651/4885PSMB5 52/4885PSMB8 1639/4885 |
| US-20150290277-A1 | PHARMACEUTICAL COMPOSITION | BCAT2, TTR, BCAT1 | LONP1 1651/4885PSMB5 52/4885PSMB8 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.